FREEDOM* FROM BLEEDS
WITH A ONCE-MONTHLY PEN1
Normalise thrombin generation** and FVIII bioequivalence with the next-generation, ultra-potent† FVIIIa mimetic1–5
FPO
Hero media — final campaign asset TBD
FREHEMGO® is indicated for routine prophylaxis of bleeding episodes in patients with hemophilia A (congenital coagulation FVIII deficiency) with or without FVIII inhibitors1
FREHEMGO® is the only†† once-monthly, ultra-potent‡ HA PPx that offers:1–4,6
FPONormal levels all month long
Normalised thrombin generation, FVIII bioequivalence and clot structure all month long. FPO
Discover the innovation
FPOThe freedom* of zero bleeds
Halved bleed rates vs FVIII PPx and a mean ABR of just 0.7, freeing 90% of patients from spontaneous bleeds. FPO
Explore efficacy data
FPOAdministration made simple
Less than a mL, less than a minute and almost no injection pain with a preferred pen. FPO
Discover dosingContact us
Our Novo Nordisk representatives are here to help